EGFR Tyrosine Kinase Inhibitor
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for EGFR Tyrosine Kinase Inhibitor, covering 2014-03-18 to 2025-01-23. Get the full timeline:
Most recent: Clinical Trial Update: Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients [Phase 1, Phase 2]